Vidac Pharma is a clinical-stage biopharmaceutical company that is committed to developing groundbreaking medicines to assist individuals who are impacted by various oncologic and dermatologic diseases. With a focus on addressing significant unmet medical needs, Vidac Pharma employs an innovative platform technology that targets hexokinase 2 (HK2), a key metabolic regulator in cancer cells. By modulating HK2's interaction with the mitochondria, Vidac's therapies induce tumor apoptosis and reduce immunosuppression in the tumor microenvironment, all while leaving healthy tissue unharmed.

Founded by Prof. Max Herzberg, a prominent figure in the Israel life sciences field, Vidac has obtained technology licenses from top Israeli universities. Their flagship product, VDA-1102 ointment, is currently in clinical development for treating actinic keratosis (AK) and has shown promising results in Phase 2 trials.

Additionally, a Phase 2 trial for cutaneous T cell lymphoma (CTCL) has recently commenced. With a commitment to efficacy and tolerability, Vidac Pharma is leading the way in pioneering therapeutics